We are a development stage pharmaceutical company that seeks to acquire, develop and commercialize innovative products for the treatment of a variety of human diseases. Our strategy is to develop pharmaceutical products that address important unmet medical needs or offer improved alternatives to current methods of treatment. We are focused on evaluating strategic opportunities while also planning for the commercialization of Northera™ (droxidopa), a novel therapeutic agent, for the treatment of symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure (Parkinson’s disease, or PD, multiple systems atrophy, or MSA, and pure autonomic failure, or PAF), dopamine β-hydroxylase, or DBH, deficiency and non-diabetic autonomic neuropathy. Northera was granted accelerated approval for marketing in the United States by the U.S. Food and Drug Administration, or FDA, in February 2014, with a commitment for an additional confirmatory study.
![Chelsea Therapeutics International logo](https://files.capedge.com/424B5/0001193125-11-354616/g275603g52c54.jpg)
Company profile
Ticker
CHTP
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203174202
Latest filings (excl ownership)
15-12G
Securities registration termination
3 Jul 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
Latest ownership filings
SC 13G
Chelsea Therapeutics International, Ltd.
28 May 14
SC 13G
Chelsea Therapeutics International, Ltd.
14 Feb 14
SC 13G/A
Chelsea Therapeutics International, Ltd.
14 Feb 14
SC 13G/A
Chelsea Therapeutics International, Ltd.
3 Feb 14
SC 13G
Chelsea Therapeutics International, Ltd.
28 Jan 14
SC 13D/A
Chelsea Therapeutics International, Ltd.
21 Nov 13
SC 13D/A
Chelsea Therapeutics International, Ltd.
17 Jun 13
SC 13D/A
AUSTIN JOSIAH T
4 Mar 13
SC 13D/A
AUSTIN JOSIAH T
19 Dec 12
SC 13D/A
AUSTIN JOSIAH T
6 Jul 12